Clarithromycin (clarithromycin): Reviews and patient testimonials

Clarithromycin 125 mg/5ml suspension

Clarithromycin 125 mg/5 ml suspension is indicated in adults, adolescents and children, 6 months to 12 years, for the treatment of the following acute and chronic infections, when caused by clarithromycin susceptible organisms.

• Infections of the upper respiratory tract such as tonsillitis/pharyngitis, as an alternative when beta lactam antibiotics are not appropriate.

• Acute otitis media in children.

• Infections of the lower respiratory tract such as community acquired pneumonia.

• Sinusitis and acute exacerbation of chronic bronchitis in adults and adolescents over 12 years of age

• Skin infections and soft tissue infections of mild to moderate severity.

In appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing medicinal product for the eradication of Helicobacter pylori in adult patients with H. pylori associated ulcers. See section 4.2.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 125mg/5ml Oral Suspension

Clarithromycin 125mg/5ml Oral Suspension is indicated in children, 6 months to 12 years.

Clarithromycin 125mg/5ml Oral Suspension is indicated for treatment of the following infections in children when caused by clarithromycin-susceptible organisms:

- Lower respiratory tract infections (e.g. bronchitis, pneumonia) see section 4.4 and 5.1 regarding Sensitivity Testing).

- Upper respiratory tract infections (e.g. pharyngitis, sinusitis).

- Skin and skin structure infections (e.g. folliculitis, cellulitis, erysipelas) see section 4.4 and 5.1 regarding Sensitivity Testing).

- Acute otitis media.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 250 mg Film-coated Tablets

Clarithromycin Tablets are indicated for treatment of infections caused by clarithromycin-susceptible organisms. Indications include:

Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia.

Upper respiratory tract infections for example, sinusitis and pharyngitis.

Clarithromycin is indicated for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity (such as cellulitis, pyoderma, impetigo).

Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of Helicobacter pylori in patients with duodenal ulcers. See section 4.2.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin is indicated in adults and children aged 12 years and older.

Clarithromycin 250 mg film-coated tablets

Clarithromycin film-coated tablets are indicated for the treatment of the following bacterial infections, when caused by clarithromycin-susceptible bacteria (see section 4.4 and 5.1).

• Bacterial pharyngitis

• Mild to moderate community acquired pneumonia

• Acute bacterial sinusitis (adequately diagnosed)

• Acute exacerbation of chronic bronchitis

• Skin infections and soft tissue infections of mild to moderate severity,

• In appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing agent for the eradication of Helicobacter pylori in patients with Helicobacter pylori associated ulcers.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 250 mg/5ml suspension

Clarithromycin 250 mg/5 ml suspension is indicated in adults, adolescents and children, 6 months to 12 years, for the treatment of the following acute and chronic infections, when caused by clarithromycin susceptible organisms.

• Infections of the upper respiratory tract such as tonsillitis/pharyngitis, as an alternative when beta lactam antibiotics are not appropriate.

• Acute otitis media in children.

• Infections of the lower respiratory tract such as community acquired pneumonia.

• Sinusitis and acute exacerbation of chronic bronchitis in adults and adolescents over 12 years of age

• Skin infections and soft tissue infections of mild to moderate severity.

In appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing medicinal product for the eradication of Helicobacter pylori in adult patients with H. pylori associated ulcers. See section 4.2.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 250mg Film-coated Tablets

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin is indicated in adults and children 12 years and older.

Clarithromycin Tablets are indicated for treatment of the following infections caused by susceptible organisms. Indications include:

Lower respiratory tract infections for example acute and chronic bronchitis, and pneumonia.

Upper respiratory tract infections for example sinusitis and pharyngitis.

Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity.

Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. (See section 4.2, Posology and method of administration).

Clarithromycin is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae.

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Clarithromycin has bactericidal activity against several bacterial strains. The organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Clarithromycin 250mg Tablets

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin is indicated in adults and children 12 years and older. (Adult only formulations, e.g. tablets, IV)

Clarithromycin Tablets are indicated for treatment of the following infections caused by susceptible organisms Indication include:

Lower respiratory tract infections for example: acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).

Upper respiratory tract infections for example: sinusitis and pharyngitis.

Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).

Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. See Dosage and Administration section.

Clarithromycin is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Clarithromycin has bactericidal activity against several bacterial strains. The organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Clarithromycin 250mg/5ml Oral Suspension

Clarithromycin 250mg/5ml Oral Suspension is indicated in children, 6 months to 12 years.

Clarithromycin 250mg/5ml Oral Suspension is indicated for treatment of the following infections in children when caused by clarithromycin-susceptible organisms:

- Lower respiratory tract infections (e.g. bronchitis, pneumonia) see section 4.4 and 5.1 regarding Sensitivity Testing).

- Upper respiratory tract infections (e.g. pharyngitis, sinusitis).

- Skin and skin structure infections (e.g. folliculitis, cellulitis, erysipelas) see section 4.4 and 5.1 regarding Sensitivity Testing).

- Acute otitis media.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 500 mg film-coated tablets

Clarithromycin film-coated tablets are indicated for the treatment of the following bacterial infections, when caused by clarithromycin-susceptible bacteria (see section 4.4 and 5.1).

• Bacterial pharyngitis

• Mild to moderate community acquired pneumonia

• Acute bacterial sinusitis (adequately diagnosed)

• Acute exacerbation of chronic bronchitis

• Skin infections and soft tissue infections of mild to moderate severity,

• In appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing agent for the eradication of Helicobacter pylori in patients with Helicobacter pylori associated ulcers.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 500 mg Film-coated Tablets

Clarithromycin Tablets are indicated for treatment of infections caused by clarithromycin-susceptible organisms. Indications include:

Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia.

Upper respiratory tract infections for example, sinusitis and pharyngitis.

Clarithromycin is indicated for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity (such as cellulitis, pyoderma, impetigo).

Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of Helicobacter pylori in patients with duodenal ulcers. See section 4.2.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin is indicated in adults and children aged 12 years and older.

Clarithromycin 500 mg, Powder for Concentrate for Solution for Infusion

Clarithromycin 500 mg, powder for concentrate for solution for infusion is indicated when parenteral therapy is required for treatment of infections, caused by clarithromycin-susceptible organisms in the following conditions:

- Community acquired pneumonia

- Acute exacerbation of chronic bronchitis

- Acute bacterial sinusitis (adequately diagnosed)

- Bacterial pharyngitis and tonsillitis

- Skin and soft tissue infections

Clarithromycin 500 mg, powder for concentrate for solution for infusion is indicated in adults and children 12 years and older.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 500mg Film-coated Tablets

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin is indicated in adults and children 12 years and older.

Clarithromycin Tablets are indicated for treatment of the following infections caused by susceptible organisms. Indications include:

Lower respiratory tract infections for example acute and chronic bronchitis, and pneumonia.

Upper respiratory tract infections for example sinusitis and pharyngitis.

Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity.

Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. (See section 4.2, Posology and method of administration).

Clarithromycin is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae.

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Clarithromycin has bactericidal activity against several bacterial strains. The organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Clarithromycin 500mg powder for solution for infusion vials

Clarithromycin 500 mg Powder for Solution for Infusion is indicated whenever parenteral therapy is required for treatment of infections caused by susceptible organisms in the following conditions:

- Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia.

- Upper respiratory tract infections for example, sinusitis and pharyngitis.

- Skin and soft tissue infections.

Clarithromycin 500 mg Powder for Solution for Infusion is indicated in adults.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin 500mg Tablets

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Clarithromycin is indicated in adults and children 12 years and older. (Adult only formulations, e.g. tablets, IV)

Clarithromycin Tablets are indicated for treatment of the following infections caused by susceptible organisms Indication include:

Lower respiratory tract infections for example: acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).

Upper respiratory tract infections for example: sinusitis and pharyngitis.

Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.

Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity e.g. folliculitis, cellulitis, erysipelas (see section 4.4 and 5.1 regarding Sensitivity Testing).

Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. See Dosage and Administration section.

Clarithromycin is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Clarithromycin has bactericidal activity against several bacterial strains. The organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Route of administration: Injectable, Oral
Molecule: clarithromycin